Australia
First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level
HIGHLIGHTS * Undetectable levels of Prostate Specific Antigen (PSA) have been reported from the first patient with metastatic castrate-resistant prostate cancer (mCRPC) to ever receive two cycles of Clarity's67Cu-SAR-bisPSMA at the 8GBq dose level. PSA is a marker of tumour burden, clinical re...
Leading AI decisioning platform Rich Data Co successfully raises $17.5 million in Series B round to accelerate North America expansion
SYDNEY, Nov. 29, 2023 /PRNewswire/ -- Rich Data Co
Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort
HIGHLIGHTS * Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67 Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has enrolled and treated 3 participants who received therapy with67Cu-SAR-bisPSMA at the highest dose level of 12GBq. * No dose limiting toxicit...
Telstra Broadcast Services and BT Announce Strategic Alliance to Enhance Global Network Connectivity
Initial five-year agreement delivers expanded media and broadcast network footprint acrossAsia-Pacific and key regions worldwide, with enhanced access to global markets SYDNEY, Nov. 21, 2023 /PRNewswire/ -- Telstra Broadcast Services (TBS) and BT have entered into an initial five-year strateg...
First Subject Enrolled in Phase 1 Study of MRX-5
SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. (hereinafter referred to as "MicuRx") announced that its proprietary antibiotic MRX-5, has enrolled its first subject in the first Phase I clinical trial inAustralia. MRX-5 is a new type of benzodiazepine...
HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO
SYDNEY, Nov. 13, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment ofDamian Clarke-Bruce as Managing Director and CEO, effective13 November 2023. Outgoing CEO Bryce Carmine will remain active in the company, retaining his role as Cha...
6clicks GRC Platform Adds Automated Cybersecurity Incident Tracking and Reporting to Meet New SEC Disclosure Requirements
Platform Now Helps Organizations Compile Details of Qualifying Events Centrally
for Tracking, Reporting, and Complete Auditability to Ensure Full Compliance
and Ease of Management
MELBOURNE, Australia, Nov. 13, 2023 /PRNewswire/ -- 6clicks
PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE
* PYC has developed a new drug candidate for the >5 million people worldwide [1] with Polycystic Kidney Disease (PKD) * This drug candidate has demonstrated efficacy in human models derived from the kidneys of patients with end-stage renal failure due to PKD[2] * PKD is a life-changing diseas...
Beyond2020 Improves Access to Clean Water for 10,000 Rural Malaysians
* Sustainable water fountains in 25 rural Malaysian communities provide clean, safe water, reducing waterborne illnesses ABU DHABI, UAE, Nov. 9, 2023 /PRNewswire/ -- Beyond2020, the UAE-driven humanitarian initiative, has installed water filters in 25 communities in theSabah and Sarawak regions...
Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial
SYDNEY, Nov. 7, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that 50 patients have no...
David Beckham Signs Deal with TEMPUR to Promote The Benefits Of Sleep
LONDON, Nov. 6, 2023 /PRNewswire/ -- TEMPUR, a leading designer, manufacturer,
distributor, and retailer of premium bedding products worldwide, has today
announced the signing ofDavid Beckham as its newest brand ambassador.
PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.
* Melbourne ophthalmology company PolyActiva is developing a unique biodegradable ocular implant that provides 6 months of sustained drug delivery for patients with glaucoma, the second most common cause of irreversible blindness. * The interim Phase 2a results demonstrate a sustained >20% re...
CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CHM 2101, A NOVEL CDH17 CAR T CELL THERAPY FOR ADVANCED GASTROINTESTINAL CANCERS
* FDA IND Clearance for CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy * Anticipated to be the first CDH17 CAR T cell therapy to enter the clinic * Phase 1A clinical trial to initiate patient enrolment in 2024 * Phase 1A clinical trial will enroll patients with advanced Colorecta...
Clarity and PSI kick off SAR-bisPSMA Phase III
SYDNEY, Oct. 26, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, and PSI CRO AG ("PSI"), a global contract rese...
Enfinity Global to partner with Kyushu Electric Power in its operational portfolio in the United States
MIAMI, Oct. 26, 2023 /PRNewswire/ -- Enfinity Global Inc., a leader in renewable energy, today announced a definitive agreement for a minority sale in its 400 MW U.S. operating portfolio to the Japanese utility Kyushu Electric Power Co. Inc. (Kyushu Electric). Upon completion of the deal, Kyushu ...
Enfinity Global & ICG complete €400 million equity agreement
MIAMI, Oct. 25, 2023 /PRNewswire/ -- Enfinity Global, a leader in renewable energy, today announced the successful completion of €300 million equity funding from ICG, the global alternative asset manager. Another €100 million of equity funding is expected to close within a one-year period as part...
Xailient and Morse Micro Join Forces to Transform the Future of Smart Cameras
Wi-Fi HaLow™ Technology Enables Long-Range, Low-Power Connectivity for Smart Cameras SYDNEY and IRVINE, Calif., Oct. 25, 2023 /PRNewswire/ -- Xailient, the leader in edge artificial intelligence (AI) for computer vision, today announced a strategic partnership with Morse Micro, a fast-growing fa...
Certa Therapeutics' FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic Sclerosis
MELBOURNE, Australia, Oct. 23, 2023 /PRNewswire/ -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation ...
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston
Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases SYDNEY, Oct. 13, 2023 /PRNewswire/ -- Acti...
AACR OVARIAN CANCER CONFERENCE PRESENTATION
HIGHLIGHTS * Data from preclinical studies in ovarian cancer presented at premier international conference inBoston, USA. * Results indicate that Amplia's proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade ser...
Week's Top Stories
Most Reposted
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 294 media titles]
2026-10-22 22:35SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 282 media titles]
2026-10-19 13:18Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 276 media titles]
2026-10-21 15:00DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Carro Establishes Inaugural SGD450 Million Asset-Backed Securitisation Warehouse Facility
[Picked up by 267 media titles]
2026-10-22 11:00